Skip to main content
. 2011 Apr 6;52(3):543–546. doi: 10.3349/ymj.2011.52.3.543

Fig. 3.

Fig. 3

Changes in bone turnover and bone mineral density (BMD) in response to zoledronic acid. L-spine BMD decreased by 5.3% from 0.678 to 0.642 g/cm2 over 3 years; C-telopeptide was suppressed by 45.8% from 0.107 to 0.058 ng/mL over the first 2 years but increased to 0.167 ng/mL over the recent 1 year; and osteocalcin gradually decreased by 60.4% from 15.42 to 6.10 ng/mL during the follow-up period after 3 years of treatment.